Dow Down1.50% Nasdaq Down2.41%

Prima Biomed Ltd. (PBMD)

-NasdaqGM
0.94 Down 0.03(3.19%) Jun 27, 4:00PM EDT
ProfileGet Profile for:
Prima Biomed Ltd.
95 Pitt Street
Level 12
Sydney, NSW 2000
Australia - Map
Phone: 61 2 8315 7003
Fax: 61 2 8569 1880
Website: http://www.primabiomed.com.au

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:N/A

Business Summary 

Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunotherapeutic products for the treatment of cancer. Its lead product candidate is IMP321, a recombinant protein, which is in phase II clinical trials in metastatic breast cancer when used as a chemo-immunotherapy. The company’s other products include IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. It also develops CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. The company has collaboration with NEC Corporation and Yamaguchi University. Prima BioMed Ltd. is based in Sydney, Australia.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Prima Biomed Ltd.

Key Executives 
 PayExercised
Mr. Marc Voigt , 43
Chief Exec. Officer, Chief Financial Officer, Chief Bus. Officer, Exec. Director, Member of Audit & Risk Committee and Member of Remuneration Committee
257.00KN/A
Dr. Frédéric Triebel M.D., Ph.D., 61
Chief Scientific Officer and Chief Medical Officer
97.00KN/A
Ms. Deanne Miller LLB, 39
Gen. Counsel and Company Sec. (Leave of absence)
193.00KN/A
Mr. Thomas Robert John Bloomfield BA (Hons), ACIS, MAICD,
Joint Company Sec.
N/AN/A
Ms. Larisa Chisholm ,
Director of Industry Liaison & Devel. and Director of Intellectual Property
N/AN/A
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.